Results 101 to 110 of about 64,314 (239)

Circulating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.

open access: yes, 2016
The relationship between tumour necrosis factor-alpha (TNF-α) and drug survival had not been studied in juvenile idiopathic arthritis (JIA) and there were no laboratory tests to predict the long-term efficacy of biological drugs for JIA.
Geborek, Pierre   +18 more
core   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Off-label uses of etanercept in dermatology

open access: yes, 2016
Tumour necrosis factor alpha (TNFα) is a key molecule involved in the inflammatory response and thus related to the pathogenesis of several autoimmune and autoinflammatory diseases.
Victoria de la Fuente-García   +2 more
core   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

open access: yesInternational Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study [PDF]

open access: yes, 2013
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital, Prato, ItalyBackground: The aim of this study was to evaluate the proportion of patients with ankylosing ...
Niccoli L   +4 more
core  

Lung Sarcoidosis in Etanercept Treated Rheumatoid Arthritis Patient: A Case Report and Review of the Literature

open access: yesCase Reports in Rheumatology, 2014
We report a 55-year-old female with seropositive rheumatoid arthritis for 10 years who developed large mediastinal and hilar adenopathy while receiving etanercept therapy.
Supat Thongpooswan, Adriana Abrudescu
doaj   +1 more source

Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis : 104-week results from a randomized, placebo-controlled study

open access: yes, 2017
Objective. To evaluate the long-term clinical and imaging efficacy of etanercept in patients with early, active nonradiographic axial spondyloarthritis (SpA). Methods.
Logeart, Isabelle   +47 more
core   +1 more source

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato   +4 more
wiley   +1 more source

Impact of methotrexate and etanercept drugs on serum levels of soluble toll-like receptor-2 in Iraqi patients with rheumatoid arthritis

open access: yesEgyptian Rheumatology and Rehabilitation
Background Methotrexate and Etanercept are common treatment strategies for rheumatoid arthritis (RA) and are classified as conventional synthetic and biologic disease-modifying antirheumatic drugs respectively.
Muna R. Hameed   +2 more
doaj   +1 more source

Etanercept – A culprit agent in acute pancreatitis?

open access: yes, 2019
Drugs are responsible for 3%-5% of acute pancreatitis cases. There are a lot of medications that are known to cause acute pancreatitis, however only one case has been reported so far on Etanercept.
Tania Octaria Mihardja   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy